Recent News About Abbott
By Business Daily | May 1, 2025
Abbott and MotoAmerica have announced a collaboration to implement a rapid blood test for evaluating concussions at motorcycle races.
By Business Daily | Apr 29, 2025
Abbott has announced a groundbreaking collaboration with Epic to integrate data from its FreeStyle Libre continuous glucose monitoring (CGM) systems directly into Epic's electronic health record systems in the United States.
By Business Daily | Apr 27, 2025
Abbott has announced significant developments in its AVEIR Conduction System Pacing (CSP) technology, which were presented during the Heart Rhythm Society's 46th annual meeting in San Diego and published in the Heart Rhythm Journal.
By Business Daily | Apr 26, 2025
Abbott has announced the 12-month results of its Volt CE Mark Study, demonstrating the safety and efficacy of the Volt PFA System for patients receiving pulsed field ablation (PFA) therapy to treat atrial fibrillation (AFib).
By Business Daily | Apr 2, 2025
Abbott introduced a new delivery system for its Proclaim DRG neurostimulation technology, which aims to streamline implantation procedures for electrodes targeting the dorsal root ganglion (DRG).
By Business Daily | Mar 31, 2025
Abbott has released new data from its TRILUMINATE Pivotal trial, revealing that the TriClip system for transcatheter edge-to-edge repair (TEER) eases the severity of tricuspid regurgitation (TR) symptoms.
By Business Daily | Mar 27, 2025
Abbott has announced it received CE Mark in Europe for the Volt Pulsed Field Ablation (PFA) System, intended for treating atrial fibrillation (AFib).
By Business Daily | Mar 26, 2025
Abbott will release its financial results for the first quarter of 2025 on April 16, before the market opens.
By Business Daily | Mar 24, 2025
Abbott has announced that the U.S. Food and Drug Administration (FDA) has approved an investigational device exemption (IDE) for its Coronary Intravascular Lithotripsy (IVL) System.
By K. R. Nelson | Feb 26, 2025
Shedd Aquarium and Abbott have announced a significant corporate donation, with Abbott and its philanthropic foundation, Abbott Fund, pledging $10 million.
By A. I. Benavidez | Feb 21, 2025
The board of directors of Abbott has announced a quarterly common dividend of 59 cents per share.
